Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
28 mars 2024 08h05 HE
|
Agile Therapeutics, Inc.
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility...
Agile Therapeutics Announces Delisting from Nasdaq
25 mars 2024 16h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company...
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
21 mars 2024 06h35 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial...
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
20 mars 2024 08h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial...
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
13 mars 2024 07h31 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has paid-off the...
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
22 févr. 2024 09h01 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a...
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
15 févr. 2024 16h30 HE
|
Agile Therapeutics, Inc.
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be...
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
23 janv. 2024 09h29 HE
|
Agile Therapeutics, Inc.
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden...
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
12 déc. 2023 08h01 HE
|
Agile Therapeutics, Inc.
The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the...
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 08h05 HE
|
Agile Therapeutics, Inc.
Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter...